ES2063801T3 - 3BETA, 17BETA-HYDROXY-SUBSTITUTED STEROIDS AND RELATED STEROID COMPOUNDS. - Google Patents

3BETA, 17BETA-HYDROXY-SUBSTITUTED STEROIDS AND RELATED STEROID COMPOUNDS.

Info

Publication number
ES2063801T3
ES2063801T3 ES89120006T ES89120006T ES2063801T3 ES 2063801 T3 ES2063801 T3 ES 2063801T3 ES 89120006 T ES89120006 T ES 89120006T ES 89120006 T ES89120006 T ES 89120006T ES 2063801 T3 ES2063801 T3 ES 2063801T3
Authority
ES
Spain
Prior art keywords
compounds
hydroxy
17beta
3beta
steroid compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89120006T
Other languages
Spanish (es)
Inventor
O'neal J Johnston
Gene W Holbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2063801T3 publication Critical patent/ES2063801T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silicon Polymers (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to a group of compounds which are 3 beta ,17 beta -hydroxy steroids, and related steroidal structures. These compounds are aromatase inhibitors, and thus, regulate or inhibit the conversion of androgens to estrogens. These compounds may be utilized to treat conditions potentiated by the presence of estrogens. These compounds exhibit a slower onset of action and a longer half life relative to the 10-(2-alkynyl) steroidal aromatase inhibitors disclosed in U.S. Patent 4,322,416.
ES89120006T 1988-10-27 1989-10-27 3BETA, 17BETA-HYDROXY-SUBSTITUTED STEROIDS AND RELATED STEROID COMPOUNDS. Expired - Lifetime ES2063801T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/263,091 US4882322A (en) 1988-10-27 1988-10-27 3β,17β-hydroxy-substituted steroids and related steroidal compounds

Publications (1)

Publication Number Publication Date
ES2063801T3 true ES2063801T3 (en) 1995-01-16

Family

ID=23000340

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89120006T Expired - Lifetime ES2063801T3 (en) 1988-10-27 1989-10-27 3BETA, 17BETA-HYDROXY-SUBSTITUTED STEROIDS AND RELATED STEROID COMPOUNDS.

Country Status (18)

Country Link
US (1) US4882322A (en)
EP (1) EP0366144B1 (en)
JP (1) JP2750621B2 (en)
KR (1) KR900006360A (en)
CN (1) CN1042363A (en)
AT (1) ATE111478T1 (en)
AU (1) AU619608B2 (en)
CA (1) CA2001264C (en)
DE (1) DE68918219T2 (en)
DK (1) DK533189A (en)
ES (1) ES2063801T3 (en)
FI (1) FI895084A0 (en)
HU (1) HU204065B (en)
IL (1) IL92103A0 (en)
NO (1) NO173097C (en)
NZ (1) NZ231107A (en)
PT (1) PT92113B (en)
ZA (1) ZA898025B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166201A (en) * 1990-11-30 1992-11-24 Merrell Dow Pharmaceuticals Inc. 2β,19-ethylene bridged steroids as aromatase inhibitors
US6372712B1 (en) 1998-05-22 2002-04-16 The Board Of Trustees Of The Leland Stanford Jr. University Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand
AU2004318212A1 (en) * 2003-11-24 2005-10-20 Merck & Co., Inc. Estrogen receptor modulators
US20070099880A1 (en) * 2003-11-24 2007-05-03 Blizzard Timothy A Estrogen receptor modulators
PT1889198E (en) 2005-04-28 2015-03-06 Proteus Digital Health Inc Pharma-informatics system
EP1945240B1 (en) 2005-09-16 2016-12-28 Raptor Pharmaceutical Inc Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2010095940A2 (en) 2009-02-20 2010-08-26 To-Bbb Holding B.V. Glutathione-based drug delivery system
NZ596876A (en) 2009-05-06 2014-01-31 Lab Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
CN103555806B (en) * 2013-11-16 2015-05-13 江南大学 Method for synthesizing 7alpha-hydroxy-androstenone by efficient utilization of colletotrichum lini

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322416A (en) * 1980-06-27 1982-03-30 Merrell Dow Pharmaceuticals Inc. 10-Alkynyl steroids
GB8531747D0 (en) * 1985-12-24 1986-02-05 Erba Farmitalia 10beta-alkynylestrene derivatives

Also Published As

Publication number Publication date
EP0366144A1 (en) 1990-05-02
IL92103A0 (en) 1990-07-12
PT92113B (en) 1995-06-30
AU619608B2 (en) 1992-01-30
DK533189D0 (en) 1989-10-26
KR900006360A (en) 1990-05-08
DE68918219T2 (en) 1995-02-02
DE68918219D1 (en) 1994-10-20
US4882322A (en) 1989-11-21
NO894276D0 (en) 1989-10-26
NO173097C (en) 1993-10-27
CA2001264A1 (en) 1990-04-27
CN1042363A (en) 1990-05-23
EP0366144B1 (en) 1994-09-14
NO894276L (en) 1990-04-30
NO173097B (en) 1993-07-19
NZ231107A (en) 1992-03-26
FI895084A0 (en) 1989-10-26
HU204065B (en) 1991-11-28
JP2750621B2 (en) 1998-05-13
PT92113A (en) 1990-04-30
CA2001264C (en) 2001-05-01
HUT52113A (en) 1990-06-28
ATE111478T1 (en) 1994-09-15
HU895457D0 (en) 1990-01-28
JPH02174793A (en) 1990-07-06
ZA898025B (en) 1990-07-25
DK533189A (en) 1990-04-28
AU4367989A (en) 1990-05-31

Similar Documents

Publication Publication Date Title
ES2063801T3 (en) 3BETA, 17BETA-HYDROXY-SUBSTITUTED STEROIDS AND RELATED STEROID COMPOUNDS.
NO20065784L (en) Steroidal compounds and their use
MX9304541A (en) 17-SPYROMETHYLENE STERIODS.
ES2132249T3 (en) PREPARATION PROCEDURE FOR 3-ALPHA-HYDROXY, 3-BETA SUBSTITUTED PREGNANES.
GR1000597B (en) Growth suspension agent and use thereof
DK396284A (en) 17BETA METHOXYCARBONYL DERIVATIVES OF THE ANDROSTAN SERIES AND THEIR PREPARATION AND USE
ES2133582T3 (en) HETERO-CYCLE STEROIDS OF C17 DELTA16-UNSATURATED USEFUL AS INHIBITORS OF STEROID C17-20 LIASA.
AU562646B2 (en) 1-alkyl-androsta-1, 4-diene-3, 17-diones
DK0582458T3 (en) Preparations for topical administration of spironolactone
ATE152119T1 (en) NEW 16-METHYL SUBSTITUTED STEROID DERIVATIVES OF PREGNA-1,4-DIENE-3,20-DIONE, THEIR PREPARATION, THEIR USE FOR PRODUCING 16-METHYLENE SUBSTITUTED STEROIDS AND NEW INTERMEDIATE PRODUCTS THEREOF
NO864365D0 (en) PROCEDURE FOR THE PREPARATION OF 1-METHYL-15ALFA-ALKYL-ANDROSTA-1,4-DIENE-3,17-DIONE.
WO1990015067A3 (en) NOVEL METHODS FOR OBTAINING 6-METHYL 19-NOR STEROIDS AND CONVERTING THEM INTO 17α-SUBSTITUTED 19-NOR PREGNADIENES
NZ237559A (en) Halogenoethyl steroid derivatives and pharmaceutical compositions
JPS5777698A (en) 18-substituted pregn-4-ene-3,20-dione
RU95113491A (en) NEW STEROIDS, METHOD OF TREATMENT, PHARMACEUTICAL COMPOSITION, METHODS OF OBTAINING
SE8600828L (en) STEROID DERIVATIVES IN THE ANDROSTAN SERIES

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 366144

Country of ref document: ES